Laurus Labs Announces Record Date for FY26 Interim Dividend
Laurus Labs Limited has announced May 8, 2026, as the official record date for determining shareholder eligibility for its second interim dividend for the financial year 2025-26. Investors holding shares of the company as of the record date will qualify to receive the declared dividend payout.
The announcement follows the company’s board meeting held on April 30, 2026, where the Board of Directors approved an interim dividend of ₹1.20 per equity share. Each equity share carries a face value of ₹2, and the dividend translates to a payout of 60% on the face value.
The development has drawn attention from investors tracking dividend-paying pharmaceutical stocks and companies with a consistent distribution history.
Dividend Payment Scheduled After May 20
According to the company’s disclosure, the dividend amount will be credited or dispatched on or after May 20, 2026. Shareholders whose names are reflected in the company’s records on the record date will be entitled to receive the payout.
Dividend eligibility is determined based on the ex-dividend timeline and settlement process followed by stock exchanges. Investors generally need to purchase shares before the ex-date to qualify for dividend benefits.
The latest interim dividend reflects an increase compared with Laurus Labs’ earlier payouts over the last two financial years.
Company Maintains Consistent Dividend Trend
Laurus Labs has regularly announced interim dividends in recent years. The company declared interim dividends of ₹0.80 per share in October 2025 and May 2025. Prior to that, shareholders received ₹0.40 per share in November 2024 and May 2024.
The newly announced ₹1.20 dividend represents the highest interim payout declared by the company in this recent period. The increase reflects the company’s continued dividend distribution approach and focus on rewarding shareholders through periodic payouts.
Dividend-paying stocks often remain in focus among market participants looking at long-term shareholder return trends and stable cash distribution histories.
Dividend Calculation for Retail Investors
For shareholders holding 100 equity shares of Laurus Labs on the record date, the declared dividend of ₹1.20 per share would result in a total payout of ₹120 before applicable taxes.
The final credited amount may vary depending on tax deductions applicable under prevailing dividend taxation rules.
Laurus Labs and Investor Focus
Laurus Labs operates in the pharmaceutical and active pharmaceutical ingredients (API) segment and remains closely tracked by market participants due to its export-focused business and presence in global healthcare markets.
Corporate actions such as dividends, stock splits, bonus issues, and buybacks generally influence investor sentiment and trading activity around record dates.
The latest dividend announcement comes amid continued interest in companies maintaining regular shareholder distribution policies despite changing market conditions.
Conclusion
Laurus Labs’ decision to fix May 8, 2026, as the record date for its second interim dividend of FY26 marks another step in the company’s ongoing dividend distribution practice. Eligible shareholders will receive ₹1.20 per share, with payments scheduled on or after May 20, 2026. The announcement also reflects a higher payout compared to previous interim dividends declared by the company in recent years.
Summary
Laurus Labs Limited has fixed May 8, 2026, as the record date for its second interim dividend for FY26. The company’s board approved a dividend of ₹1.20 per equity share of face value ₹2 each. Eligible shareholders whose names appear in company records on the record date will receive the dividend payment on or after May 20, 2026. The latest payout is higher than previous interim dividends declared by the pharmaceutical company, continuing its regular shareholder reward practice.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.
